Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Chinese researchers identify potential new antibiotic
LONDON, Sept.
Perrigo's OTC Version of Diarrhea Drug Imodium Gets FDA Nod
Perrigo Company plc PRGO announced that the FDA has approved store brand over-the-counter ("OTC") equivalent of Johnson & Johnson JNJ owned Imodium Multi-Symptom Relief tablet.
Vertex Completes Enrollment of Two Phase 3 Studies of VX-659 in Triple Combination with Tezacaftor and Ivacaftor for the Treatment of Cystic Fibrosis
BOSTON, MA, USA I September 06, 2018 I Vertex Pharmaceuticals Incorporated (Nasdaq.
ITF Pharma Announces FDA Approval Of TIGLUTIK™ (Riluzole) Oral Suspension For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)
BERWYN, PA, USA I September 6, 2018 I ITF Pharma, a U.
BTG buys Irish med device group Novate
Specialist healthcare group BTG has snapped up med tech group Novate Medical in a deal potentially worth $150 million.
Gilead, Galapagos’ filgotinib succeeds in PhII ankylosing spondylitis trial
A mid-stage trial assessing Gilead and Galapagos’ JAK 1 inhibitor filgotinib in ankylosing spondylitis has hit its targets.
GlaxoSmithKline to cut 650 US jobs, reinvest in R & D
RALEIGH, N.
Walking 20 minutes a day cuts women's heart failure risk by 25%, first ever study on the topic reveals
Walking more - not faster - can significantly lower the risk of heart failure in older women, according to the first ever study on the subject.
Novartis unloads U.S. assets at loss to bargain-hunting Aurobindo
ZURICH/BENGALURU (Reuters) - New Novartis Chief Executive Vas Narasimhan has further reshaped the Swiss drugmaker, announcing on Thursday he is selling U.
Teva drops development of laquinimod
Teva Pharmaceutical Industries has decided not to pursue development of laquinimod, and has returned rights to the drug back to Swedish group Active Biotech.
As Brexit costs mount, Pfizer estimates $100M to adapt its supply chain
In yet another indication of what the burden of Brexit will be for drug manufacturers, Pfizer has said that it has tallied its costs to revise its manufacturing and supply chain at about $100 million.
Scientists find a new way to understand odors
Every smell, from a rose to a smoky fire to a pungent fish, is composed of a mixture of odorant molecules that bind to protein receptors inside your nose.
443
444
445
446
447
448
449
450
451
